Literature DB >> 26873379

Lobar distribution in non-cystic fibrosis bronchiectasis predicts bacteriologic pathogen treatment.

S Izhakian1,2,3, W G Wasser4, L Fuks5, B Vainshelboim5, B D Fox5, O Fruchter5, M R Kramer5.   

Abstract

Non-cystic fibrosis bronchiectasis (NCFBr) is a major cause of morbidity due to frequent infectious exacerbations. We analyzed the influence of patient age and bronchiectasis location on the bacterial profile of patients with NCFBr. This retrospective cohort study included 339 subjects diagnosed with an infectious exacerbation of NCFBr during the 9-year period between January 2006 and December 2014. Bronchoalveolar lavage (BAL) cultures and high-resolution computed tomography scans (HRCT) were utilized to characterize the location of the bronchiectasis and bacteriologic pathogenic profile. In univariate logistic regression, the frequency of Haemophilus influenzae was higher in patients aged ≤64 years (OR = 0.969, p < 0.0001, 95 % CI 0.954-0.983), whereas the frequency of Pseudomonas aeruginosa (OR = 1.027, p = 0.008, 95 % CI 1.007-1.048) and Enterobacteriaceae (OR = 1.039, p = 0.01, 95 % CI 1.009-1.069) were significantly higher in patients aged >64 years. The lobar distribution of bronchiectasis in the subjects was 25.9 % in the right middle lobe (RML), 20.7 % in the right lower lobe (RLL), 20.4 % in the left lower lobe (LLL), 13.8 % in the lingula, 13 % in the right upper lobe (RUL), and 6.2 % in the left upper lobe (LUL). In the lower lobes, H. influenzae was the dominant species isolated, whereas in the RUL it was P. aeruginosa and in the LUL it was non- tuberculous mycobacterium (NTM). H. influenzae was more prevalent in younger patients, whereas P. aeruginosa, Enterobacteriaceae and NTM predominated in older patients. Different pathogens were associated with different lobar distributions. The RML, RLL and LLL showed a greater tendency to develop bronchiectasis than other lobes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26873379     DOI: 10.1007/s10096-016-2599-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  An investigation into causative factors in patients with bronchiectasis.

Authors:  M C Pasteur; S M Helliwell; S J Houghton; S C Webb; J E Foweraker; R A Coulden; C D Flower; D Bilton; M T Keogan
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

2.  Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors.

Authors:  J Angrill; C Agustí; R de Celis; A Rañó; J Gonzalez; T Solé; A Xaubet; R Rodriguez-Roisin; A Torres
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

3.  Clinical, laboratory findings and microbiologic characterization of bronchiectasis in Thai patients.

Authors:  Apirak Palwatwichai; Chutima Chaoprasong; Anan Vattanathum; Adisorn Wongsa; Anon Jatakanon
Journal:  Respirology       Date:  2002-03       Impact factor: 6.424

4.  Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.

Authors:  C B Wilson; P W Jones; C J O'Leary; D M Hansell; P J Cole; R Wilson
Journal:  Eur Respir J       Date:  1997-08       Impact factor: 16.671

5.  CT of airways disease and bronchiectasis.

Authors:  Georgeann McGuinness; David P Naidich
Journal:  Radiol Clin North Am       Date:  2002-01       Impact factor: 2.303

6.  Non-tuberculous mycobacteria in patients with bronchiectasis.

Authors:  M Wickremasinghe; L J Ozerovitch; G Davies; T Wodehouse; M V Chadwick; S Abdallah; P Shah; R Wilson
Journal:  Thorax       Date:  2005-10-14       Impact factor: 9.139

7.  Mortality in bronchiectasis: a long-term study assessing the factors influencing survival.

Authors:  M R Loebinger; A U Wells; D M Hansell; N Chinyanganya; A Devaraj; M Meister; R Wilson
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

8.  Microbiologic follow-up study in adult bronchiectasis.

Authors:  Paul T King; Stephen R Holdsworth; Nicholas J Freezer; Elmer Villanueva; Peter W Holmes
Journal:  Respir Med       Date:  2007-04-30       Impact factor: 3.415

9.  Mycobacteria as a cause of infective exacerbation in bronchiectasis.

Authors:  C H Chan; A K Ho; R C Chan; H Cheung; A F Cheng
Journal:  Postgrad Med J       Date:  1992-11       Impact factor: 2.401

10.  Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance.

Authors:  Melissa J McDonnell; Hannah R Jary; Audrey Perry; James G MacFarlane; Katy L M Hester; Therese Small; Catherine Molyneux; John D Perry; Katherine E Walton; Anthony De Soyza
Journal:  Respir Med       Date:  2014-08-29       Impact factor: 3.415

View more
  4 in total

1.  Morphological features of bronchiectasis in patients with non-tuberculous mycobacteriosis and interstitial pneumonia.

Authors:  Chiori Tabe; Masaki Dobashi; Yoshiko Ishioka; Masamichi Itoga; Hisashi Tanaka; Kageaki Taima; Sadatomo Tasaka
Journal:  BMC Res Notes       Date:  2022-07-26

2.  Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006-2021: a systematic review and meta-analysis.

Authors:  Yunchun Zhou; Wei Mu; Jihua Zhang; Shi Wu Wen; Smita Pakhale
Journal:  BMJ Open       Date:  2022-08-01       Impact factor: 3.006

3.  Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations.

Authors:  Rosario Menéndez; Raúl Méndez; Eva Polverino; Edmundo Rosales-Mayor; Isabel Amara-Elori; Soledad Reyes; José Miguel Sahuquillo-Arce; Laia Fernández-Barat; Victoria Alcaraz; Antoni Torres
Journal:  BMC Infect Dis       Date:  2017-09-30       Impact factor: 3.090

Review 4.  Antimicrobial Resistance in Common Respiratory Pathogens of Chronic Bronchiectasis Patients: A Literature Review.

Authors:  Riccardo Inchingolo; Chiara Pierandrei; Giuliano Montemurro; Andrea Smargiassi; Franziska Michaela Lohmeyer; Angela Rizzi
Journal:  Antibiotics (Basel)       Date:  2021-03-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.